CSG  - Strategies for research and marketing success
Home News Clinical Research Consulting Medical Services Career Research
Home
Contact Imprint Search

CSG - Strategies for research and marketing success

First Interim Results of HAROW Study available

Never before has so much information been collected on the treatment of the newly diagnosed, locally confined prostate cancer under ordinary, everyday conditions. The data of 5,000 patients are intended to provide a solid foundation for the discussion of what is considered to be the right therapy decision. Responsible for the implementation of the study and the evaluation of the results is the CSG corporation which also participated in the overall design of the study. A decisive factor in this was CSG’s extensive expertise in the field of oncological studies; in particular, prostate cancer. The study was initiated by the Stiftung Männergesundheit [Men’s Health Foundation] in Berlin. As an observational health care study, the HAROW study pursues the objective of finding adequate curative health care forms while considering not only the quality of life but also the individual needs and requirements of the patients. The study examines all types of prostate cancer therapies at the same time which, in turn, explains the study’s acronym:
H = Hormonal Therapy
A = Active Surveillance
R = Radiotherapy
O = Operation
W = Watchful Waiting
HAROW is a non-interventional, prospective health care study, i.e. it observes and documents under ordinary, everyday conditions without exerting influence on the type and implementation of the therapy. Ideally, the HAROW data will serve as the basis for a new direction in doctors’ recommendations (guideline) and for health care directives. Prof. Dr. med. Lothar Weißbach is the scientific supervisor, and a scientific advisory board accompanies the study.
Until the end of October 2009, HAROW recruited more than 1,000 men who were newly diagnosed with prostate cancer. The results of the first interim evaluation are now available.
Mehr ...

 
Clinical Research
Clinical research of the highest technological level
[Mehr]
Consulting
Competent consulting at all stages of product development
[Mehr]
Medical Services
Comprehensive strategies for your product within the healthcare market
[Mehr]

CSG bridges the gap between clinical research and strategic marketing.

a contract research organization we conduct clinical trials and post-marketing surveillance at the highest procedural standards, guaranteeing cost efficient design for your studies through modern data capture technologies..

Our consulting service helps optimize your study design and portfolio. Health economics aspects can be integrated from the start. We provide post-marketing surveillance through projects on medical care management or quality control.

CSG is ready to meet the challenge posed by today's constantly changing public health system.
We offer an overall concept for clinical research that opens new horizons for all phases of product development.

CSG works closely with IGES Institut, Germany´s largest privately owned institute for research and consulting in Healthcare.

CSG in Berlin-Mitte

Home

From now on CSG is located in Berlin-Mitte, in the historical Quartier 110. Our new Address:
CSG mbH, Friedrichstraße 180, 10117 Berlin. Our phone and fax numbers will remain unchanged. – Please note: you can also organize your conferences at our location, in the Auditorium Friedrichstrasse: www.auditorium-friedrichstrasse.de

 
Conceptual – planning of clinical studies; CRO – full service – study planning; Moderation – position development [more ...]
CSG -From clinical trials to market success [more ...]
Activities
Activities
October 11-13th, 2010,

DIA 4th Annual Clinical Forum, Lisbon
"Theme 4: Peri-and Post-Approval Studies", Heike Schön (CSG): Programme Sub Committee and Session Chair: Session 8, 13th October 2010; 11:00 a.m., "Post-Approval Observational Studies - The Perspective of European Countries", see alsohttp://www.diahome.org
Innovation Prize for Haemophilia Project
HaemoassistTM Makes a Vital Contribution towards Improving the Transparency and Assuring the Quality of Haemophilia Therapy [more ...]
  Sitemap   Printversion 
© 2014 Clinische Studien Gesellschaft, Berlin